Andre Joshi1,2,3,4,5, Matthew J Roberts1,6,7, Saeid Alinezhad2,3,4, Elizabeth D Williams2,3,4, Ian Vela1,2,3,4,5. 1. Department of Urology, Princess Alexandra Hospital, Brisbane, Qld, Australia. 2. Australian Prostate Cancer Research Centre-Queensland, Brisbane, Qld, Australia. 3. Translational Research Institute, Brisbane, Qld, Australia. 4. School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, Qld, Australia. 5. Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia. 6. University of Queensland Centre for Clinical Research, The University of Queensland, Herston, Qld, Australia. 7. Department of Urology, Royal Brisbane and Women's Hospital, Herston, Qld, Australia.
Abstract
OBJECTIVE: To provide a clinically relevant outline of various current precision medicine principles and available evidence on the application and potential for a precision medicine approach in prostate cancer. METHODS: Narrative review of the current literature in the field. CONCLUSION: Precision medicine is the concept of individualising patient management based on specific tumour characteristics and biology, rather than traditional histological subtypes. The overall aim is to personalise management to individual patients, to provide the right cancer treatment, to the right patient, at the right time. While the approach aims to improve clinical outcomes, decrease morbidity and improve survival in men with advanced prostate cancer, its clinical application is in its infancy. It does however show great promise in this and other cancers, and will continue to be an area of active research and clinical investigation.
OBJECTIVE: To provide a clinically relevant outline of various current precision medicine principles and available evidence on the application and potential for a precision medicine approach in prostate cancer. METHODS: Narrative review of the current literature in the field. CONCLUSION: Precision medicine is the concept of individualising patient management based on specific tumour characteristics and biology, rather than traditional histological subtypes. The overall aim is to personalise management to individual patients, to provide the right cancer treatment, to the right patient, at the right time. While the approach aims to improve clinical outcomes, decrease morbidity and improve survival in men with advanced prostate cancer, its clinical application is in its infancy. It does however show great promise in this and other cancers, and will continue to be an area of active research and clinical investigation.
Authors: Erika Heninger; David Kosoff; Tamara S Rodems; Nan Sethakorn; Anupama Singh; Harshitha Gungurthi; Kristin N Carlson; Bing Yang; Cole Gilsdorf; Cheri A Pasch; Dustin A Deming; Leigh Ellis; David J Beebe; David F Jarrard; Joshua M Lang Journal: Med Oncol Date: 2021-09-28 Impact factor: 3.738